Skip to main content

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia



Clozapine is the treatment of choice in refractory psychosis. In most countries, clozapine must be stopped indefinitely if white blood cells fall below a defined threshold during routine monitoring. Despite evidence of severe adverse consequences of clozapine discontinuation, published accounts on the lived experiences and perspectives of patients and carers are scarce.


We completed semi-structured interviews with patients (n = 4) and family carers (n = 4) on experiences of clozapine cessation following suspected drug-induced neutropenia. Interviews were audio-recorded, transcribed and analysed thematically.


The two overarching themes comprised:(i) stress of clozapine below threshold neutrophil results and (ii) patient and carer priorities.


There is a suggested need for evidence-based pharmacological and psychological approaches to support patients and carers after clozapine cessation. Such approaches will minimise the potentially negative physical and emotional sequela in the aftermath of a below threshold neutrophil result and reduce the likelihood of experiencing additional health and social inequalities after clozapine discontinuation.

Peer Review reports


Clozapine is the most effective antipsychotic for treatment-refractory psychosis [1]. In many countries around the world, patients prescribed clozapine are required to undergo haematological monitoring indefinitely [2]. Haematological monitoring is intended to mitigate against the rare but potentially fatal risk of clozapine-induced agranulocytosis (CIA) (prevalence ~ 0.4%) [3]. The nature of clozapine monitoring systems, including absolute neutrophil count (ANC) and/or white cell counts (WCC) thresholds for categorising readings vary widely between countries [2]. As an example, in the US, absolute neutrophil count (ANC) thresholds for clozapine discontinuation are ≥ 1.0 × 109/L (or ≥ 0.5 × 109/L if there was a history of benign ethnic neutropenia [BEN]). Whereas thresholds are 0.5 × 109/L higher in the United Kingdom and countries regulated by the European Medicines Agency. Notably, the overwhelming evidence indicates that US monitoring thresholds do not compromise patient safety [1, 4,5,6]. In the event of a below threshold haematological reading, patients are required to immediately stop clozapine treatment [1]. Treatment may then be stopped indefinitely or restarted depending on the follow-up blood test results [1]. Approximately 1 in 10 patients discontinue clozapine due to suspected clozapine-induced neutropenia (CIN) [7].

The discontinuation of clozapine can have several negative clinical consequences, including withdrawal symptoms, deterioration in mental state, and reduced antipsychotic response [8, 9]. The sudden and unplanned nature of treatment discontinuation after suspected CIN may potentially have greater implications for both patients and carers. Accordingly, public health authorities have prioritised identifying ‘true’ CIN, as the current system is believed to vastly overestimate CIN and underestimate non-clozapine causes such as benign neutropenia [1, 4, 10, 11].

At present, the cumbersome nature of investigations for these potential differentials coupled with clinician hesitancy means that safely restarting treatment (i.e. clozapine rechallenge) is often delayed, if done at all [4]. To date, there has been little qualitative exploration of the lived experience, including reported needs, from patients and family carers following a below threshold haematological result and having to stop clozapine [12]. Understanding these experiences may assist care providers to provide optimal support and resources for patients and key others in their networks. Therefore, in people with lived experience of treatment resistant psychosis, their family and carers, we aimed to qualitatively explore their perspectives of discontinuing clozapine treatment after a haematological abnormality.


Study setting and ethical considerations

This was a qualitative, cross-sectional study which used semi-structured interviews. The study was conducted in the South London and Maudsley NHS Foundation Trust (SLaM), a large Inner London hospital, and approved by the local Drugs and Therapeutic Committee (approval number: DTC/2022/35). SLaM provides mental health services to 1·2 million people across four South London boroughs.


A reflexive thematic analysis methodology [13] was used for this study, to allow for the identification of themes across the dataset that could give specific ideas for systemic change [14].


An interview topic guide was developed and used for all interviews by one author (EO), which was informed by clinical expertise, wider reference to the literature [8, 9] and iteratively refined via ongoing discussions with the research team. All participants were encouraged to introduce issues of importance not covered by the topic guide (see supplementary material for further details). Data generation and analysis were conducted in parallel using constant comparative technique with incoming data informing following interviews [15]. Data collection continued until the point of information power, which was classified regarding how well the data collected addressed the aims of this study, rather than when no new data emerged [16, 17].


Patients and carers of those who previously experienced a red below threshold neutrophil result while treated with clozapine between January to September 2022 were recruited for interviews. This 6 month time span was chosen to include individuals who may have been rechallenged on clozapine after a confirmed red below threshold result with sufficient time to recall their experiences [1]. Participants were initially identified by EO and EW from the clozapine registry. Once permission to approach the patient was secured, the patient was approached by EO to obtain informed written consent. Sociodemographic and clinical information (e.g., age, sex) was retrieved from medical notes. Interviews were held via Microsoft teams. Participants were compensated £10 for their time.

Data Analysis

The interviews were analysed using Reflexive Thematic Analysis [13] within a critical realist framework, which views meaning and experiences as subjective and influenced by social and cultural context. An inductive approach was used to analyse the data. Thus, analysis was conducted in a bottom-up approach, allowing the data to lead the formulation of themes, rather than predefining themes or utilising a theoretical approach [18].

Participants were aware of the researcher’s (EO) status when taking part in the interviews but were informed that it was their own experiences that were of relevance to the research. Participants were also reassured that all views given were valid and important, to prevent them from feeling they had to provide only positive views. There were no existing relationships between the research team and participants. To ensure that this influence was acknowledged during the research process, the lead author employed reflective practice in the form of continuous debriefing with the wider research team (JO, E.W, DD).

Interviews were audio-recorded and transcribed verbatim. Identifying information was removed at transcription and recordings were destroyed. The two analysing authors (DD, JO) were guided by the explicit content of the data rather than making assumptions or looking at existing concepts [13, 14], as this approach felt it would be most informative for systematic change.

The six phases of thematic analysis outlined by Braun and Clarke were followed [18]. The analysing authors (DD, JO) achieved data familiarisation by reading and re-reading transcripts several times, followed by manual coding and final clustering and synthesis of codes to form themes.

Coding drew out key themes, words, and phrases and themes were generated independently prior to analysing authors meeting to discuss findings. No software was used during the analysis. It comprised constant comparison, with the relationships between codes explored alongside an analysis of each code across the transcripts. Conducting the analysis concurrent with data collection ensured iterative interaction between data and analysis to enhance reliability [19].

Through regular meetings, with time between for reflection, themes were revisited and reviewed. Quality checks were performed by comparing a random sample of recordings to transcripts. The wider research team met to review and refine the themes, which were discussed against the coded data and the final themes and subthemes were agreed. A final consensus was reached on the themes that best reflected the data.

Overall reliability was established by probing the relationship between each individual transcript and the themes across the interviews as well as through discussions within the research team to forge shared interpretations. Drawing upon multiple researcher perspectives is advocated as a way of increasing the credibility and therefore the trustworthiness, of the final analysis [15, 20].



From the twelve patients who had a recorded neutropenic event during the study period, four (1 male and 3 females) agreed to participate (33%). Individual interviews were conducted with four patients and four related carers. The mean length of interviews was 43 min.

Patients had an average age of 39 years and were prescribed clozapine for a mean of 9 years (range: 2–18). All patients had a diagnosis of paranoid schizophrenia. One of the patients had been re-challenged on clozapine after the haematological event. One patient discontinued clozapine treatment after the haematological event due to frequent monitoring requirements.


Analysis of interview data identified two core themes that speak to (1) the negative psychological sequelae of recording haematological aberrations with clozapine treatment and (2) calls for improvements to care and service delivery. (Table 1): report these.

Table 1 The overall theme and subthemes that emerged from the interview


Study findings

The eight participants in our study described physical and psychological challenges from recording neutropenia and its aftercare. Key themes included the negative psychological impact of suspected CIN and patient and care priorities. Despite potentially life-changing consequences, patients and carers described a lack of effective communication and care planning after receiving a haematological aberration with clozapine. The preliminary findings from our modest pilot investigation suggests patients and carers may experience cessation of clozapine owing to neutropenia as a catastrophic event.

Comparison to other studies

To date, studies of patient, family or carer experiences with clozapine treatment have primarily focussed on clinical aspects such as symptom changes, tolerability and mandatory haematological monitoring and have often neglected the psychological impact of recording neutropenia, sudden unplanned treatment discontinuation and its aftercare [12]. Notwithstanding, studies in other medical specialities support our observation that an illness’s diagnostic uncertainty and potential recurrence may result in trauma-related psychological disturbances [21]. For example, fear of cancer recurrence is a significantly distressing problem that affects a substantial number of patients with and survivors of cancer and is often the most frequently endorsed unmet need [21]. Within this perspective it is plausible that comparable clinical needs are shared with individuals and families who experience suspected CIN, particularly once rechallenged on treatment.


For patients and carers, recorded haematological aberrations with clozapine treatment were associated with feelings of worry, uncertainty, anxiety, and service abandonment. For carers, specifically, the sense of being neglected by services and being left in the dark about what was likely to occur in their relative’s health and mitigation plans and/or solutions were particularly highlighted. Patients and carers described experiencing elevated levels of distress and adjustment difficulties and described the process that followed the neutropenia notification and their experiences as being traumatic. Patients and carers felt unsupported and not adequately informed about the potential consequences of recording neutropenia with clozapine treatment. Patients and carers expressed a lack of contingency and prevention planning, despite the potential prognostic impact of clozapine discontinuation and the role that information was likely to have in reducing levels of anxiety and uncertainty. Our analysis suggests that clozapine monitoring systems distinctly prioritise physical health over mental health and deemphasise long-term mental health care for patients with TRP. Previous studies have demonstrated how haematological thresholds and unrecognition of BEN can lead to unnecessary clozapine discontinuation. Of note, BEN is believed to predominantly associated with people of African, middle eastern, and Caribbean ancestry, and so the problem of inappropriate clozapine cessation may disproportionately affect people of these ancestries [10, 11].

It is crucial to identify and address the unique needs of families and carers during a haematological aberration with clozapine. For example, our interviews revealed a period of heightened anxiety during follow-up investigations and monitoring. Understandably, the realisation that a relative may experience a potentially fatal reaction coupled with the need to abruptly stop the only treatment that has succeeded in symptom alleviation can be disabling and associated with varied emotional reactions including anxiety, worry and fear. Notably, carers described disappointment with healthcare providers’ responses to their lived experiences and expressed concerns and found their lack of understanding, avoidance and poor communication particularly difficult to accept. Uncertainty with care plans, processing medical information, and complex decision-making regarding whether to rechallenge clozapine made the initial period of aftercare particularly overwhelming. Recognising and addressing these needs should be equally prioritised by care providers and remain consistent with treatment and good practice guidelines.


Our study is limited by the small sample size and its confinement to one care setting. Nevertheless, to our knowledge, this is the first study of its kind to explore patient and carer experiences of a haematological aberration with clozapine. Moreover, CIA is a rare event (incidence 0.4%) [22]. It is of note that our patient interviewees were community dwelling and engaged with their pharmacological treatments, including clozapine, and most had a favourable view of clozapine before the haematological aberration. It is unclear if individuals with unfavourable views of clozapine and/or residing in different settings (e.g. psychiatric inpatient care) would express share similar views. It is conceivable, however, that irrespective of thoughts about clozapine, the diagnostic follow-up and the impact of abrupt clozapine discontinuation (e.g. withdrawal symptoms), are consistently burdensome among all patients. Furthermore, our study is limited by our involvement in data collection as healthcare professionals.

Clinical implications and future studies

Our findings have important implications for clinical practice. Around 1 in 10 people taking clozapine are forced to stop taking it because of haematological toxicity [7]. However, it is estimated that 1 in 250 people experience a true agranulocytosis [22]. The vast majority of those stopping clozapine can be safely re-exposed to clozapine, indicating that clozapine had been stopped unnecessarily. The catastrophic nature of sudden cessation of clozapine should be considered when stopping clozapine [9]. Equally, providing psychosocial support for carers and patients is crucial. Thoughtful and careful assessment and the development of appropriate treatment pathways can optimise the detection and management of distress and traumatic stress. For example, clozapine discontinuation after a suspected haematological aberration should not be automatic. Instead, this should prompt clinicians to investigate differential causes of neutropenia such as viral infections, concomitant medication, or BEN. Moreover, service providers should strongly consider providing clinicians with access to training and resources such as evidence-based guidelines and expert opinion to support patient care, including identification and treatment of potential withdrawal symptoms and alternative treatment options during clozapine interruption. Second, interviewees highlighted the importance of being able to remain in the community, receiving a contingency plan, and timely information on potential outcomes after clozapine discontinuation. It seems important to consider these issues and anticipate the potential occurrence of haematological aberrations with clozapine. Patients and carers should be counselled on haematological monitoring requirements and potential consequences prior to treatment initiation. Interestingly, categorising test results using a traffic-light system was considered unnecessarily anxiety-provoking, especially considering potential non-clozapine causes. Universal use of US classification may address this issue [1]. Future studies should investigate the impact of the recurrence of such events on patient and family perspectives and the impact of professional support.

Availability of Data and Materials

The data that support the findings of this study cannot be made publicly available for confidentiality reasons. Data are however available from the corresponding author upon reasonable request.


  1. Oloyede E, Whiskey E, Casetta C, et al. Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study. The Lancet Psychiatry. 2022.

    Article  PubMed  Google Scholar 

  2. Oloyede E, Blackman G, Whiskey E, et al. Clozapine haematological monitoring for neutropenia: a global perspective. Epidemiol Psychiatric Sci. 2022;31:e83. 2022/11/25.

    Article  Google Scholar 

  3. Xiao-Hong L, Xiao-Mei Z, Lu L, et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med. 2020;50:583–94.

    Article  Google Scholar 

  4. Oloyede E, Casetta C, Dzahini O et al. There Is Life After the UK Clozapine Central Non-Rechallenge Database. Schizophr Bull 2021 2021/02/05. DOI:

  5. Whiskey E, Dzahini O, Ramsay R, et al. Need to bleed? Clozapine haematological monitoring approaches a time for change. Int Clin Psychopharmacol. 2019;34:264–8.

    Article  PubMed  Google Scholar 

  6. Sultan RS, Olfson M, Correll CU, et al. Evaluating the effect of the changes in FDA guidelines for clozapine monitoring. J Clin Psychiatry. 2017;78:0–0.

    Article  Google Scholar 

  7. Legge SE, Hamshere M, Hayes RD, et al. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res. 2016;174:113–9. 2016/05/19.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Blackman G, Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. Therapeutic Adv Psychopharmacol. 2021;11:20451253211032053.

    Article  Google Scholar 

  9. Blackman G, Oloyede E, Horowitz M, et al. Reducing the risk of withdrawal symptoms and relapse following Clozapine Discontinuation—Is it feasible to develop evidence-based guidelines? Schizophr Bull. 2021.

    Article  PubMed Central  Google Scholar 

  10. Oloyede E, Dzahini O, Barnes N, et al. Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals. BMC Psychiatry. 2021;21:502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Legge SE, Pardiñas AF, Helthuis M, et al. A genome-wide association study in individuals of african ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Mol Psychiatry. 2019;24:328–37. 2019/01/15.

    Article  CAS  PubMed  Google Scholar 

  12. Parkes S, Mantell B, Oloyede E, et al. Patients’ Experiences of Clozapine for treatment-resistant Schizophrenia: a systematic review. Schizophrenia Bull Open. 2022.

    Article  Google Scholar 

  13. Byrne D. A worked example of Braun and Clarke’s approach to reflexive thematic analysis. Qual Quant. 2022;56:1391–412.

    Article  Google Scholar 

  14. Clarke V, Braun V. Successful qualitative research: a practical guide for beginners. Success Qualitative Res 2013: 1–400.

  15. Peters S. Qualitative research methods in mental health. Royal Coll Psychiatrists, 2010, p. 35–40.

  16. Malterud K, Siersma V, Guassora A. Sample size in qualitative interview studies. Qualitative Health Research. Sage Journals. 2016;26:1753–60.

    Google Scholar 

  17. Braun V, Clarke V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qualitative Res Psychol. 2021;18:328–52.

    Article  Google Scholar 

  18. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3:77–101.

    Article  Google Scholar 

  19. Morse JM, Barrett M, Mayan M, et al. Verification strategies for establishing reliability and validity in qualitative research. Int J qualitative methods. 2002;1:13–22.

    Article  Google Scholar 

  20. Tracy SJ. Qualitative quality: eight “big-tent” criteria for excellent qualitative research. Qualitative Inq. 2010;16:837–51.

    Article  Google Scholar 

  21. Palmer SC, Kagee A, Coyne JC, et al. Experience of trauma, distress, and posttraumatic stress disorder among breast cancer patients. Psychosom Med. 2004;66:258–64.

    Article  PubMed  Google Scholar 

  22. Li X-H, Zhong X-M, Lu L, et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med. 2020;50:583–94.

    Article  PubMed  Google Scholar 

Download references


We would like to thank the patients and carers interviewed during the study. We would also like to thank the SLaM Psychosis Clinical Academic Group Service User Advisory Group for their non-financial support.


The study did not receive direct funding.

Author information

Authors and Affiliations



E.O, E.W and J.O contributed to the conception and design of the study. E.O, D.D and collected, analysed and E.O, D.D, E.W and J.O interpreted the data. E.O wrote the main manuscript text. D.D prepared the table. All authors contributed to the drafting and revision of the manuscript.

Corresponding author

Correspondence to Ebenezer Oloyede.

Ethics declarations

Ethical approval and consent to participate

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human subjects/patients were approved by the South London and Maudsley NHS Foundation Trust Drugs and Therapeutic Committee (Approval number: DTC/2022/35). Informed consent was obtained from all subjects and/or their legal guardian(s). The interviews were recorded for transcription with the participants’ agreement and all data from the interviews were handled confidentially. The interview data were anonymized before being presented in the results, in such a way that no individual can be identified.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oloyede, E., Dunnett, D., Taylor, D. et al. The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia. BMC Psychiatry 23, 413 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: